Compare Regeneron Pharmaceuticals Inc (REGN) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Symbotic Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $745.9 (market cap $76.14B), while Symbotic Inc trades at $42.69 (market cap $5.46B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 13.9× Symbotic Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Symbotic Inc for 23 Days on average.
| REGN | SYM | |
|---|---|---|
Market Cap | $76.14B | $5.46B |
Volume | 500,239 | 1,965,805 |
Sector | Health | Industrials |
52-Week High | $852.03 | $87.30 |
52-Week Low | $557.73 | $38.22 |
Typical Hold Time | 107 Days | 23 Days |
Enterprise Value | $70.85B | $3.72B |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
SYM trades at $43.31, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported negative net income of -$16.94M for 2025 despite $2.25B revenue, though 2026 projections show improvement to $8M net profit. Analysts maintain a buy consensus with a $60.33 price target, representing 39% upside potential from current levels.
SYM presents growth potential with a massive $22.5B backlog and expanding robotics/AI market, but faces significant customer concentration risk (85% revenue from Walmart) and recent earnings misses. The stock appears undervalued with a P/E of 1.05, though high EV/EBITDA of 74.05 suggests premium valuation relative to current earnings power.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
